drugset / Trial / NCT06295094
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
Phase 2
Not yet recruiting
264 enrolled
Odense University Hospital
Karolinska University Hospital · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The goal of this randomized clinical trial is to investigate whether pressurized intraperitoneal chemotherapy (PIPAC), delivered immediately after minimally invasive D2 gastrectomy and repeated 6-8 weeks later, improves 12-month peritoneal disease-free survival in patients with high-risk gastric adenocarcinoma when compared to standard treatment.
Timeline
- Start
- 2024-09
- Primary completion
- 2027-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 10.5 mg/m2 | Other |
| Subject | Doxorubicin | Other / unclassified | 2.1 mg/m2 | Other |